@article{b1e8a4393c6e4b64a5be878996ff45e5,
title = "Concurrent chemoradiotherapy for inoperable stage III non-small-cell lung cancer",
abstract = "Chemoradiotherapy has become the standard treatment for patients with locally advanced non-small-cell lung cancer on the basis of several large randomized trials. Despite an increase in median survival from 10 months with radiotherapy alone to 16 to 17 months with concurrent chemoradiotherapy, long-term survival in this disease remains modest at best. With the advent of new biologic agents targeting specific cellular pathways associated with malignant progression, combined-modality therapy has the potential to target tumors selectively with less toxicity.",
author = "Robert MacRae and Hak Choy",
note = "Funding Information: Increased expression of COX-2, a key inducible enzyme involved in prostaglandin metabolism, plays a significant role in carcinogenesis in addition to its well-known role in inflammatory processes. Based on interesting preclinical data from several institutions showing that selective inhibition of COX-2 provides tumor-specific radiosensitization [24], Pyo et al. [25] have shown that a selective COX-2 inhibitor, NS-398, did not enhance the effect of radiation on cell survival in rat intestinal epithelial (RIE) cells transfected with an antisense copy of the COX-2 gene. However, RIE cells transfected with COX-2 cDNA in the sense direction demonstrated a concentration-dependent enhancement of the effect of radiation on cell survival. These findings were supported by results from xenografts in National Cancer Institute H460 human lung cancer cells that overexpressed COX-2, in which use of a specific COX-2 inhibitor enhanced the effects of ionizing radiation by a factor of 2.5. In xenografts of HCT-116 cells, which lack COX-2 expression, no significant enhancement was seen.",
year = "2003",
month = jul,
doi = "10.1007/s11912-003-0073-z",
language = "English (US)",
volume = "5",
pages = "313--317",
journal = "Current oncology reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "4",
}